Amended Statement of Beneficial Ownership (3/a)
April 05 2021 - 6:51PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Popovits Kimberly J |
2. Date of Event Requiring Statement (MM/DD/YYYY)
2/11/2021
|
3. Issuer Name and Ticker or Trading Symbol
Talis Biomedical Corp [TLIS]
|
(Last)
(First)
(Middle)
C/O TALIS BIOMEDICAL CORPORATION, 230 CONSTITUTION DRIVE |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Street)
MENLO PARK, CA 94025
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY) 2/11/2021
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Series E-1 Preferred Stock | (1) | (1) | Common Stock | 0 | (1) | I | See footnote (1) |
Explanation of Responses: |
(1) | 300,000 shares of Series E-1 preferred shares reported in the originally filed Form 3 were mistakenly identified as held by the Reporting Person's spouse. These shares are held by a non-affiliate relative of the Reporting Person. The subsequent Form 4 filed by the Reporting Person also erroneously included these indirect holdings. This Form 3/A is being filed to correct the aforementioned error. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Popovits Kimberly J C/O TALIS BIOMEDICAL CORPORATION 230 CONSTITUTION DRIVE MENLO PARK, CA 94025 | X |
|
|
|
Signatures
|
/s/ Karen E. Flick, Attorney-in-Fact for
Kimberly J. Popovits | | 4/5/2021 |
**Signature of Reporting Person | Date |
Talis Biomedical (NASDAQ:TLIS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Talis Biomedical (NASDAQ:TLIS)
Historical Stock Chart
From Apr 2023 to Apr 2024